These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1693 related articles for article (PubMed ID: 34072260)

  • 1. Hijacked Immune Cells in the Tumor Microenvironment: Molecular Mechanisms of Immunosuppression and Cues to Improve T Cell-Based Immunotherapy of Solid Tumors.
    Balta E; Wabnitz GH; Samstag Y
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34072260
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aspects of the Tumor Microenvironment Involved in Immune Resistance and Drug Resistance.
    Khalaf K; Hana D; Chou JT; Singh C; Mackiewicz A; Kaczmarek M
    Front Immunol; 2021; 12():656364. PubMed ID: 34122412
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Checkpoint blockade-based immunotherapy in the context of tumor microenvironment: Opportunities and challenges.
    Duan J; Wang Y; Jiao S
    Cancer Med; 2018 Sep; 7(9):4517-4529. PubMed ID: 30088347
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Cancer Cell Dissemination Machinery as an Immunosuppressive Niche: A New Obstacle Towards the Era of Cancer Immunotherapy.
    Asiry S; Kim G; Filippou PS; Sanchez LR; Entenberg D; Marks DK; Oktay MH; Karagiannis GS
    Front Immunol; 2021; 12():654877. PubMed ID: 33927723
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reprogramming Immune Cells for Enhanced Cancer Immunotherapy: Targets and Strategies.
    Dong Y; Wan Z; Gao X; Yang G; Liu L
    Front Immunol; 2021; 12():609762. PubMed ID: 33968014
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pushing Past the Blockade: Advancements in T Cell-Based Cancer Immunotherapies.
    Waibl Polania J; Lerner EC; Wilkinson DS; Hoyt-Miggelbrink A; Fecci PE
    Front Immunol; 2021; 12():777073. PubMed ID: 34868044
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overcoming Resistance to Combination Radiation-Immunotherapy: A Focus on Contributing Pathways Within the Tumor Microenvironment.
    Darragh LB; Oweida AJ; Karam SD
    Front Immunol; 2018; 9():3154. PubMed ID: 30766539
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nanoengineered Immune Niches for Reprogramming the Immunosuppressive Tumor Microenvironment and Enhancing Cancer Immunotherapy.
    Phuengkham H; Ren L; Shin IW; Lim YT
    Adv Mater; 2019 Aug; 31(34):e1803322. PubMed ID: 30773696
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor Secretome to Adoptive Cellular Immunotherapy: Reduce Me Before I Make You My Partner.
    Etxebeste-Mitxeltorena M; Del Rincón-Loza I; Martín-Antonio B
    Front Immunol; 2021; 12():717850. PubMed ID: 34447383
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tissue-Resident Memory T Cells in Cancer Immunosurveillance.
    Park SL; Gebhardt T; Mackay LK
    Trends Immunol; 2019 Aug; 40(8):735-747. PubMed ID: 31255505
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PTEN loss correlates with T cell exclusion across human cancers.
    Lin Z; Huang L; Li SL; Gu J; Cui X; Zhou Y
    BMC Cancer; 2021 Apr; 21(1):429. PubMed ID: 33874915
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Antitumor Cytotoxic Response: If the Killer Cells Play the Music, the Microenvironmental Hypoxia Plays the Tune.
    Chouaib S
    Crit Rev Immunol; 2020; 40(2):157-166. PubMed ID: 32749093
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of Immunological Treatment Effects of Virotherapy in Tumor Tissue.
    Das K; Urbiola C; Spiesschaert B; Mueller P; Wollmann G
    Methods Mol Biol; 2020; 2058():155-177. PubMed ID: 31486037
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetically Induced Tumors in the Oncopig Model Invoke an Antitumor Immune Response Dominated by Cytotoxic CD8β
    Overgaard NH; Principe DR; Schachtschneider KM; Jakobsen JT; Rund LA; Grippo PJ; Schook LB; Jungersen G
    Front Immunol; 2018; 9():1301. PubMed ID: 29930558
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Re-education of the Tumor Microenvironment With Targeted Therapies and Immunotherapies.
    Ngiow SF; Young A
    Front Immunol; 2020; 11():1633. PubMed ID: 32849557
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Tumor Microenvironment in the Response to Immune Checkpoint Blockade Therapies.
    Petitprez F; Meylan M; de Reyniès A; Sautès-Fridman C; Fridman WH
    Front Immunol; 2020; 11():784. PubMed ID: 32457745
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunosuppressive cells in tumor immune escape and metastasis.
    Liu Y; Cao X
    J Mol Med (Berl); 2016 May; 94(5):509-22. PubMed ID: 26689709
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives.
    Mao X; Xu J; Wang W; Liang C; Hua J; Liu J; Zhang B; Meng Q; Yu X; Shi S
    Mol Cancer; 2021 Oct; 20(1):131. PubMed ID: 34635121
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emerging role of metabolic reprogramming in tumor immune evasion and immunotherapy.
    Fan C; Zhang S; Gong Z; Li X; Xiang B; Deng H; Zhou M; Li G; Li Y; Xiong W; Zeng Z; Li X
    Sci China Life Sci; 2021 Apr; 64(4):534-547. PubMed ID: 32815067
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acquired resistance to cancer immunotherapy: Role of tumor-mediated immunosuppression.
    Saleh R; Elkord E
    Semin Cancer Biol; 2020 Oct; 65():13-27. PubMed ID: 31362073
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 85.